{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T04:36:44Z","timestamp":1768019804274,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Minufiya University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bladder outlet obstruction mediated underactive bladder represents a challenging condition in which transurethral resection of prostate did not prove to be a sufficient treatment option. Therefore, this study was conducted to evaluate the effects and adverse effects of Pyridostigmine as a treatment for underactive bladder after transurethral resection of prostate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective, double-blind, randomized controlled study was conducted between May 2024 and November 2024. Sixty-six patients who had benign prostatic hyperplasia with preoperative underactive bladder and eligible for transurethral resection of prostate were randomized into two groups: the Pyridostigmine group, which received Pyridostigmine 120\u00a0mg daily for 3 months postoperatively, and the control group, which received placebo postoperatively. Patients were followed-up for 3 months postoperatively to observe symptom changes, urodynamic changes and adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patient who received Pyridostigmine showed significant improvement compared to the control group patients regarding IPSS score (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001), quality of life (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), postvoid residual volume (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002), maximum flow rate (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), contractility index (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001) and postoperative retention incidence (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005). Mild adverse effects were reported in 23.5% of patients who received Pyridostigmine with no reported serious adverse effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pyridostigmine after transurethral resection of prostate in patients with underactive bladder with benign prostatic hyperplasia leads to significant improvements in postoperative subjective and objective outcomes with insignificant adverse effects and wide safety profile making Pyridostigmine a therapeutic option for enhancing bladder function recoverability after transurethral resection of prostate.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00345-025-05842-8","type":"journal-article","created":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T20:59:43Z","timestamp":1754168383000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The efficacy of pyridostigmine therapy after transurethral resection of prostate in cases with underactive urinary bladder: prospective randomized trial"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6750-6653","authenticated-orcid":false,"given":"Khaled Magdy","family":"Zeinelabden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"El-Shazly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2397-8217","authenticated-orcid":false,"given":"Ammar","family":"Alorabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossam","family":"Kandeel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baher","family":"Salman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,2]]},"reference":[{"issue":"2","key":"5842_CR1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.eururo.2013.10.015","volume":"65","author":"NI Osman","year":"2014","unstructured":"Osman NI, Chapple CR, Abrams P, Dmochowski R, Haab F, Nitti V et al (2014) Detrusor underactivity and the underactive bladder: a new clinical entity? A review of current terminology, definitions, epidemiology, aetiology, and diagnosis. Eur Urol 65(2):389\u2013398","journal-title":"Eur Urol"},{"key":"5842_CR2","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s11884-015-0331-6","volume":"10","author":"BT Kadow","year":"2015","unstructured":"Kadow BT, Tyagi P, Chermansky CJ (2015) Neurogenic causes of detrusor underactivity. Curr Bladder Dysfunct Rep 10:325\u2013331","journal-title":"Curr Bladder Dysfunct Rep"},{"issue":"1","key":"5842_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","volume":"61","author":"P Abrams","year":"2003","unstructured":"Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U et al (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the international continence society. Urology 61(1):37\u201349","journal-title":"Urology"},{"issue":"1","key":"5842_CR4","first-page":"11","volume":"15","author":"M Miyazato","year":"2013","unstructured":"Miyazato M, Yoshimura N, Chancellor MB (2013) The other bladder syndrome: underactive bladder. Rev Urol 15(1):11","journal-title":"Rev Urol"},{"issue":"4","key":"5842_CR5","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0090-4295(03)00507-7","volume":"62","author":"GA Defreitas","year":"2003","unstructured":"Defreitas GA, Lemack GE, Zimmern PE, Dewey RB, Roehrborn CG, O\u2019Suilleabhain PE (2003) Distinguishing neurogenic from non-neurogenic detrusor overactivity: a urodynamic assessment of lower urinary tract symptoms in patients with and without parkinson\u2019s disease. Urology 62(4):651\u2013655","journal-title":"Urology"},{"issue":"4","key":"5842_CR6","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/MOU.0b013e32832ce8a4","volume":"19","author":"K-E Andersson","year":"2009","unstructured":"Andersson K-E, Chapple CR, Cardozo L, Cruz F, Hashim H, Michel MC et al (2009) Pharmacological treatment of overactive bladder: report from the international consultation on incontinence. Curr Opin Urol 19(4):380\u2013394","journal-title":"Curr Opin Urol"},{"issue":"6","key":"5842_CR7","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.urology.2004.07.031","volume":"64","author":"B Djavan","year":"2004","unstructured":"Djavan B, Chapple C, Milani S, Marberger M (2004) State of the Art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 64(6):1081\u20131088","journal-title":"Urology"},{"issue":"1","key":"5842_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/nau.24839","volume":"41","author":"C Moro","year":"2022","unstructured":"Moro C, Phelps C, Veer V, Clark J, Glasziou P, Tikkinen KA et al (2022) The effectiveness of parasympathomimetics for treating underactive bladder: a systematic review and meta-analysis. Neurourol Urodyn 41(1):127\u2013139","journal-title":"Neurourol Urodyn"},{"issue":"10","key":"5842_CR9","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.nmd.2022.09.002","volume":"32","author":"L Remijn-Nelissen","year":"2022","unstructured":"Remijn-Nelissen L, Verschuuren JJ, Tannemaat MR (2022) The effectiveness and side effects of pyridostigmine in the treatment of myasthenia gravis: a cross-sectional study. Neuromuscul Disord 32(10):790\u2013799","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"5842_CR10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.5152\/tud.2019.37659","volume":"45","author":"\u00d6 Bayrak","year":"2019","unstructured":"Bayrak \u00d6, Dmochowski RR (2019) Underactive bladder: a review of the current treatment concepts. Turkish J Urol 45(6):401","journal-title":"Turkish J Urol"},{"issue":"1","key":"5842_CR11","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.juro.2017.07.079","volume":"199","author":"M Kim","year":"2018","unstructured":"Kim M, Jeong CW, Oh S-J (2018) Effect of preoperative urodynamic detrusor underactivity on transurethral surgery for benign prostatic hyperplasia: a systematic review and meta-analysis. J Urol 199(1):237\u2013244","journal-title":"J Urol"},{"issue":"2","key":"5842_CR12","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.urology.2005.08.015","volume":"67","author":"N Seki","year":"2006","unstructured":"Seki N, Kai N, Seguchi H, Takei M, Yamaguchi A, Naito S (2006) Predictives regarding outcome after transurethral resection for prostatic adenoma associated with detrusor underactivity. Urology 67(2):306\u2013310","journal-title":"Urology"},{"issue":"21","key":"5842_CR13","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1001\/archinte.166.21.2381","volume":"166","author":"V Kupelian","year":"2006","unstructured":"Kupelian V, Wei JT, O\u2019Leary MP, Kusek JW, Litman HJ, Link CL et al (2006) Prevalence of lower urinary tract symptoms and effect on quality of life in a Racially and ethnically diverse random sample: the Boston area community health (BACH) survey. Arch Intern Med 166(21):2381\u20132387","journal-title":"Arch Intern Med"},{"issue":"5","key":"5842_CR14","doi-asserted-by":"publisher","first-page":"342","DOI":"10.4111\/kju.2012.53.5.342","volume":"53","author":"SJ Jeong","year":"2012","unstructured":"Jeong SJ, Kim HJ, Lee YJ, Lee JK, Lee BK, Choo YM et al (2012) Prevalence and clinical features of detrusor underactivity among elderly with lower urinary tract symptoms: a comparison between men and women. Korean J Urol 53(5):342\u2013348","journal-title":"Korean J Urol"},{"issue":"3","key":"5842_CR15","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jfma.2017.09.006","volume":"117","author":"Y-H Chang","year":"2018","unstructured":"Chang Y-H, Siu JJ-Y, Hsiao P-J, Chang C-H, Chou EC-L (2018) Review of underactive bladder. J Formos Med Assoc 117(3):178\u2013184","journal-title":"J Formos Med Assoc"},{"issue":"5","key":"5842_CR16","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.eururo.2020.06.004","volume":"78","author":"MJ Drake","year":"2020","unstructured":"Drake MJ, Lewis AL, Young GJ, Abrams P, Blair PS, Chapple C et al (2020) Diagnostic assessment of lower urinary tract symptoms in men considering prostate surgery: a noninferiority randomised controlled trial of urodynamics in 26 hospitals. Eur Urol 78(5):701\u2013710","journal-title":"Eur Urol"},{"issue":"1","key":"5842_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.5213\/inj.2346252.126","volume":"28","author":"M-S Chuang","year":"2024","unstructured":"Chuang M-S, Ou Y-C, Cheng Y-S, Wu K-Y, Wang C-T, Huang Y-C et al (2024) Surgical outcomes and predictive factors in patients with detrusor underactivity undergoing bladder outlet obstruction surgery. Int Neurourol J 28(1):59","journal-title":"Int Neurourol J"},{"issue":"5","key":"5842_CR18","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.eururo.2018.07.037","volume":"74","author":"NI Osman","year":"2018","unstructured":"Osman NI, Esperto F, Chapple CR (2018) Detrusor underactivity and the underactive bladder: a systematic review of preclinical and clinical studies. Eur Urol 74(5):633\u2013643","journal-title":"Eur Urol"},{"key":"5842_CR19","volume-title":"EAU guidelines on neuro-urology","author":"B Blok","year":"2017","unstructured":"Blok B, Castro-Diaz D, Del Popolo G, Groen J, Hamid R, Karsenty G et al (2017) EAU guidelines on neuro-urology. European Association of Urology, Arnhem"},{"issue":"Suppl 2","key":"5842_CR20","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.4111\/icu.2017.58.S2.S90","volume":"58","author":"DK Kim","year":"2017","unstructured":"Kim DK (2017) Current Pharmacological and surgical treatment of underactive bladder. Invest Clin Urol 58(Suppl 2):S90\u2013S8","journal-title":"Invest Clin Urol"},{"issue":"1","key":"5842_CR21","first-page":"10","volume":"105","author":"K Sugaya","year":"2014","unstructured":"Sugaya K, Kadekawa K, Onaga T, Ashitomi K, Mukouyama H, Nakasone K et al (2014) Effect of distigmine at 5\u00a0mg daily in patients with detrusor underactivity. Nihon Hinyokika Gakkai Zasshi 105(1):10\u201316","journal-title":"Nihon Hinyokika Gakkai Zasshi"},{"issue":"1","key":"5842_CR22","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s41598-017-18307-9","volume":"8","author":"KA Petrov","year":"2018","unstructured":"Petrov KA, Kharlamova AD, Lenina OA, Nurtdinov AR, Sitdykova ME, Ilyin VI et al (2018) Specific Inhibition of acetylcholinesterase as an approach to decrease muscarinic side effects during myasthenia Gravis treatment. Sci Rep 8(1):304","journal-title":"Sci Rep"},{"issue":"11","key":"5842_CR23","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1111\/j.1442-2042.2006.01589.x","volume":"13","author":"Y Tanaka","year":"2006","unstructured":"Tanaka Y, Masumori N, Itoh N, Furuya S, Ogura H, Tsukamoto T (2006) Is the short-term outcome of transurethral resection of the prostate affected by preoperative degree of bladder outlet obstruction, status of detrusor contractility or detrusor overactivity? Int J Urol 13(11):1398\u20131404","journal-title":"Int J Urol"},{"issue":"4","key":"5842_CR24","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.urology.2007.11.109","volume":"71","author":"DH Han","year":"2008","unstructured":"Han DH, Jeong YS, Choo M-S, Lee K-S (2008) The efficacy of transurethral resection of the prostate in the patients with weak bladder contractility index. Urology 71(4):657\u2013661","journal-title":"Urology"},{"issue":"Suppl 2","key":"5842_CR25","doi-asserted-by":"publisher","first-page":"S186","DOI":"10.21037\/tau.2017.04.07","volume":"6","author":"J Gani","year":"2017","unstructured":"Gani J, Hennessey D (2017) The underactive bladder: diagnosis and surgical treatment options. Translational Androl Urol 6(Suppl 2):S186","journal-title":"Translational Androl Urol"},{"issue":"2","key":"5842_CR26","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s004150050059","volume":"244","author":"R Beekman","year":"1997","unstructured":"Beekman R, Kuks J, Oosterhuis H (1997) Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients. J Neurol 244(2):112\u2013118","journal-title":"J Neurol"},{"key":"5842_CR27","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2165\/11593300-000000000-00000","volume":"31","author":"L Maggi","year":"2011","unstructured":"Maggi L, Mantegazza R (2011) Treatment of myasthenia gravis: focus on pyridostigmine. Clin Drug Investig 31:691\u2013701","journal-title":"Clin Drug Investig"},{"key":"5842_CR28","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3389\/fneur.2020.00604","volume":"11","author":"ME Farrugia","year":"2020","unstructured":"Farrugia ME, Goodfellow JA (2020) A practical approach to managing patients with myasthenia gravis\u2014opinions and a review of the literature. Front Neurol 11:604","journal-title":"Front Neurol"},{"issue":"2","key":"5842_CR29","doi-asserted-by":"publisher","first-page":"e00208","DOI":"10.1002\/prp2.208","volume":"4","author":"S Plan\u00e8s","year":"2016","unstructured":"Plan\u00e8s S, Villier C, Mallaret M (2016) The Nocebo effect of drugs. Pharmacol Res Perspect 4(2):e00208","journal-title":"Pharmacol Res Perspect"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05842-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05842-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05842-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T22:03:35Z","timestamp":1767996215000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05842-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,2]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5842"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05842-8","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,2]]},"assertion":[{"value":"19 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study received ethics approval from our local university ethics committee (Menoufia University Institutional Review Board) under the number 5-2024UROL3.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"We obtained informed consent from all patients prior to participating in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"473"}}